HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Carter-Wallace

This article was originally published in The Rose Sheet

Executive Summary

U.S. antiperspirant sales declined 5.5%, and worldwide sales dropped 4% to $101.6 mil. for the fiscal year ended March 31, the company reported. New introductions included Arrid XX Ultra Clear Solid in a larger size. C-W's domestic consumer products division posted a 2.4% sales growth to $283.2 mil. and operating profit was up 34.1% to $44.8 mil. Overall sales for the company grew 1% from the prior year, reaching $668.9 mil., while net earnings after expenses rose 3.3% to $28.2 mil

Latest Headlines
See All
UsernamePublicRestriction

Register

RS006960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel